Transgenic Group（2342）株式概要株式会社トランスジェニック・グループは、日本における遺伝子組換え動物および抗体の開発、販売、ライセンス供与を行っている。 詳細2342 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間62.4%減少しました。 JP市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( ¥4B )すべてのリスクチェックを見る2342 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥230.0092.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b15b2016201920222025202620282031Revenue JP¥14.7bEarnings JP¥2.7bAdvancedSet Fair ValueView all narrativesTransgenic Group Inc. 競合他社D. Western Therapeutics InstituteSymbol: TSE:4576Market cap: JP¥4.2bKohjin BioSymbol: TSE:177AMarket cap: JP¥5.5bKidswell BioSymbol: TSE:4584Market cap: JP¥7.0bPerseus ProteomicsSymbol: TSE:4882Market cap: JP¥2.3b価格と性能株価の高値、安値、推移の概要Transgenic Group過去の株価現在の株価JP¥230.0052週高値JP¥487.0052週安値JP¥152.00ベータ0.421ヶ月の変化-10.85%3ヶ月変化-20.42%1年変化51.32%3年間の変化-25.08%5年間の変化-58.26%IPOからの変化-89.35%最新ニュースReported Earnings • May 17Full year 2026 earnings released: JP¥4.62 loss per share (vs JP¥65.47 loss in FY 2025)Full year 2026 results: JP¥4.62 loss per share (improved from JP¥65.47 loss in FY 2025). Revenue: JP¥13.2b (up 1.3% from FY 2025). Net loss: JP¥77.0m (loss narrowed 93% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • May 13Transgenic Group Inc., Annual General Meeting, Jun 18, 2026Transgenic Group Inc., Annual General Meeting, Jun 18, 2026.Reported Earnings • Feb 11Third quarter 2026 earnings released: JP¥0.06 loss per share (vs JP¥6.55 loss in 3Q 2025)Third quarter 2026 results: JP¥0.06 loss per share (improved from JP¥6.55 loss in 3Q 2025). Revenue: JP¥3.47b (flat on 3Q 2025). Net loss: JP¥1.00m (loss narrowed 99% from 3Q 2025). Profit margin: 0% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.分析記事 • Jan 15Is Transgenic Group (TSE:2342) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Dec 18Transgenic Group Inc. to Report Q3, 2026 Results on Feb 10, 2026Transgenic Group Inc. announced that they will report Q3, 2026 results on Feb 10, 2026分析記事 • Nov 19Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) may be sending very bullish signals...最新情報をもっと見るRecent updatesReported Earnings • May 17Full year 2026 earnings released: JP¥4.62 loss per share (vs JP¥65.47 loss in FY 2025)Full year 2026 results: JP¥4.62 loss per share (improved from JP¥65.47 loss in FY 2025). Revenue: JP¥13.2b (up 1.3% from FY 2025). Net loss: JP¥77.0m (loss narrowed 93% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • May 13Transgenic Group Inc., Annual General Meeting, Jun 18, 2026Transgenic Group Inc., Annual General Meeting, Jun 18, 2026.Reported Earnings • Feb 11Third quarter 2026 earnings released: JP¥0.06 loss per share (vs JP¥6.55 loss in 3Q 2025)Third quarter 2026 results: JP¥0.06 loss per share (improved from JP¥6.55 loss in 3Q 2025). Revenue: JP¥3.47b (flat on 3Q 2025). Net loss: JP¥1.00m (loss narrowed 99% from 3Q 2025). Profit margin: 0% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.分析記事 • Jan 15Is Transgenic Group (TSE:2342) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Dec 18Transgenic Group Inc. to Report Q3, 2026 Results on Feb 10, 2026Transgenic Group Inc. announced that they will report Q3, 2026 results on Feb 10, 2026分析記事 • Nov 19Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) may be sending very bullish signals...Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: JP¥0.18 (vs JP¥4.99 loss in 2Q 2025)Second quarter 2026 results: EPS: JP¥0.18 (up from JP¥4.99 loss in 2Q 2025). Revenue: JP¥3.03b (down 12% from 2Q 2025). Net income: JP¥3.00m (up JP¥86.0m from 2Q 2025). Profit margin: 0.1% (up from net loss in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.お知らせ • Sep 04Transgenic Group Inc. to Report Q2, 2026 Results on Nov 12, 2025Transgenic Group Inc. announced that they will report Q2, 2026 results on Nov 12, 2025Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: JP¥1.56 (vs JP¥5.97 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥1.56 (up from JP¥5.97 loss in 1Q 2025). Revenue: JP¥3.20b (up 11% from 1Q 2025). Net income: JP¥26.0m (up JP¥125.0m from 1Q 2025). Profit margin: 0.8% (up from net loss in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.お知らせ • Jun 26Transgenic Group Inc. to Report Q1, 2026 Results on Aug 14, 2025Transgenic Group Inc. announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • Jun 19Full year 2025 earnings released: JP¥65.47 loss per share (vs JP¥0.24 profit in FY 2024)Full year 2025 results: JP¥65.47 loss per share (down from JP¥0.24 profit in FY 2024). Revenue: JP¥13.0b (flat on FY 2024). Net loss: JP¥1.09b (down JP¥1.09b from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.分析記事 • Jun 17Here's Why Transgenic Group (TSE:2342) Can Afford Some DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 17There's No Escaping Transgenic Group Inc.'s (TSE:2342) Muted Revenues Despite A 33% Share Price RiseTransgenic Group Inc. ( TSE:2342 ) shareholders would be excited to see that the share price has had a great month...お知らせ • Jun 16Transgenic Group Inc., Annual General Meeting, Jun 30, 2025Transgenic Group Inc., Annual General Meeting, Jun 30, 2025.分析記事 • Apr 15Little Excitement Around Transgenic Group Inc.'s (TSE:2342) RevenuesTransgenic Group Inc.'s ( TSE:2342 ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right...New Risk • Apr 07New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥2.73b market cap, or US$18.7m).お知らせ • Mar 12Transgenic Group Inc. to Report Fiscal Year 2025 Results on May 13, 2025Transgenic Group Inc. announced that they will report fiscal year 2025 results on May 13, 2025Reported Earnings • Feb 17Third quarter 2025 earnings released: JP¥6.55 loss per share (vs JP¥5.10 loss in 3Q 2024)Third quarter 2025 results: JP¥6.55 loss per share (further deteriorated from JP¥5.10 loss in 3Q 2024). Revenue: JP¥3.50b (up 3.9% from 3Q 2024). Net loss: JP¥109.0m (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.New Risk • Dec 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥3.03b market cap, or US$19.2m).お知らせ • Dec 04Transgenic Group Inc. to Report Q3, 2025 Results on Feb 14, 2025Transgenic Group Inc. announced that they will report Q3, 2025 results on Feb 14, 2025Reported Earnings • Nov 18Second quarter 2025 earnings released: JP¥4.99 loss per share (vs JP¥1.78 loss in 2Q 2024)Second quarter 2025 results: JP¥4.99 loss per share (further deteriorated from JP¥1.78 loss in 2Q 2024). Revenue: JP¥3.43b (up 11% from 2Q 2024). Net loss: JP¥83.0m (loss widened 177% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.分析記事 • Nov 13Transgenic Group Inc.'s (TSE:2342) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) is definitely a...Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥5.97 loss per share (vs JP¥4.63 profit in 1Q 2024)First quarter 2025 results: JP¥5.97 loss per share (down from JP¥4.63 profit in 1Q 2024). Revenue: JP¥2.88b (down 12% from 1Q 2024). Net loss: JP¥99.0m (down 227% from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Reported Earnings • Jun 26Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023)Full year 2024 results: EPS: JP¥0.24 (up from JP¥24.28 loss in FY 2023). Revenue: JP¥13.1b (up 14% from FY 2023). Net income: JP¥4.00m (up JP¥413.0m from FY 2023). Profit margin: 0% (up from net loss in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.お知らせ • Jun 20Trans Genic Inc. to Report Q1, 2025 Results on Aug 09, 2024Trans Genic Inc. announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • May 13Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023)Full year 2024 results: EPS: JP¥0.24 (up from JP¥24.28 loss in FY 2023). Revenue: JP¥13.1b (up 14% from FY 2023). Net income: JP¥4.00m (up JP¥413.0m from FY 2023). Profit margin: 0% (up from net loss in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance.お知らせ • May 12Trans Genic Inc., Annual General Meeting, Jun 20, 2024Trans Genic Inc., Annual General Meeting, Jun 20, 2024.分析記事 • Apr 27Improved Revenues Required Before Trans Genic Inc. (TSE:2342) Shares Find Their FeetTrans Genic Inc.'s ( TSE:2342 ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy right now...Upcoming Dividend • Mar 21Upcoming dividend of JP¥3.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 24 June 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.2%). In line with average of industry peers (1.2%).お知らせ • Mar 06Trans Genic Inc. to Report Fiscal Year 2024 Results on May 10, 2024Trans Genic Inc. announced that they will report fiscal year 2024 results on May 10, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥5.10 loss per share (vs JP¥7.59 profit in 3Q 2023)Third quarter 2024 results: JP¥5.10 loss per share (down from JP¥7.59 profit in 3Q 2023). Revenue: JP¥3.37b (up 15% from 3Q 2023). Net loss: JP¥86.0m (down 167% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.New Risk • Jan 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥4.45b market cap, or US$30.2m).お知らせ • Nov 29Trans Genic Inc. to Report Q3, 2024 Results on Feb 09, 2024Trans Genic Inc. announced that they will report Q3, 2024 results on Feb 09, 2024お知らせ • Nov 24Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 300,000 shares, representing 1.78% for ¥100 million.Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 300,000 shares, representing 1.78% of its issued share capital, for ¥100 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till March 22, 2024. As of November 22, 2023, the company had 16,893,719 shares issued (excluding treasury stock) and 105,422 shares in treasury.Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥4.69 profit in 2Q 2023)Second quarter 2024 results: JP¥1.78 loss per share (down from JP¥4.69 profit in 2Q 2023). Revenue: JP¥3.10b (flat on 2Q 2023). Net loss: JP¥30.0m (down 138% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Sep 15Trans Genic Inc. to Report Q2, 2024 Results on Nov 10, 2023Trans Genic Inc. announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 14First quarter 2024 earnings released: EPS: JP¥4.63 (vs JP¥1.49 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥4.63 (up from JP¥1.49 loss in 1Q 2023). Revenue: JP¥3.28b (up 33% from 1Q 2023). Net income: JP¥78.0m (up JP¥103.0m from 1Q 2023). Profit margin: 2.4% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 28Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022)Full year 2023 results: JP¥24.28 loss per share (down from JP¥110 profit in FY 2022). Revenue: JP¥11.4b (down 9.1% from FY 2022). Net loss: JP¥409.0m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Jun 21Trans Genic Inc. to Report Q1, 2024 Results on Aug 10, 2023Trans Genic Inc. announced that they will report Q1, 2024 results on Aug 10, 2023Reported Earnings • May 18Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022)Full year 2023 results: JP¥24.28 loss per share (down from JP¥110 profit in FY 2022). Revenue: JP¥11.4b (down 9.1% from FY 2022). Net loss: JP¥409.0m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Upcoming Dividend • Mar 23Upcoming dividend of JP¥5.00 per share at 0.9% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 26 June 2023. Payout ratio is a comfortable 4.0% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (1.0%).Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: JP¥7.59 (vs JP¥10.54 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥7.59 (up from JP¥10.54 loss in 3Q 2022). Revenue: JP¥2.92b (flat on 3Q 2022). Net income: JP¥128.0m (up JP¥307.0m from 3Q 2022). Profit margin: 4.4% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Dec 21Trans Genic Inc. to Report Q3, 2023 Results on Feb 10, 2023Trans Genic Inc. announced that they will report Q3, 2023 results on Feb 10, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022)Second quarter 2023 results: EPS: JP¥4.69 (down from JP¥21.50 in 2Q 2022). Revenue: JP¥3.07b (down 9.4% from 2Q 2022). Net income: JP¥79.0m (down 79% from 2Q 2022). Profit margin: 2.6% (down from 11% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Hotaka Saito was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022)Second quarter 2023 results: EPS: JP¥4.69 (down from JP¥21.50 in 2Q 2022). Revenue: JP¥3.07b (down 9.4% from 2Q 2022). Net income: JP¥79.0m (down 79% from 2Q 2022). Profit margin: 2.6% (down from 11% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Sep 02Trans Genic Inc. to Report Q2, 2023 Results on Nov 11, 2022Trans Genic Inc. announced that they will report Q2, 2023 results on Nov 11, 2022Reported Earnings • Aug 14First quarter 2023 earnings released: JP¥1.49 loss per share (vs JP¥35.01 profit in 1Q 2022)First quarter 2023 results: JP¥1.49 loss per share (down from JP¥35.01 profit in 1Q 2022). Revenue: JP¥2.47b (down 25% from 1Q 2022). Net loss: JP¥25.0m (down 104% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Jun 23Trans Genic Inc. to Report Q1, 2023 Results on Aug 12, 2022Trans Genic Inc. announced that they will report Q1, 2023 results on Aug 12, 2022Reported Earnings • May 16Full year 2022 earnings released: EPS: JP¥110 (vs JP¥31.44 in FY 2021)Full year 2022 results: EPS: JP¥110 (up from JP¥31.44 in FY 2021). Revenue: JP¥12.6b (up 14% from FY 2021). Net income: JP¥1.88b (up 244% from FY 2021). Profit margin: 15% (up from 4.9% in FY 2021). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • May 15Trans Genic Inc., Annual General Meeting, Jun 23, 2022Trans Genic Inc., Annual General Meeting, Jun 23, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Outside Director Hotaka Saito was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 07Trans Genic Inc. to Report Fiscal Year 2022 Results on May 13, 2022Trans Genic Inc. announced that they will report fiscal year 2022 results on May 13, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥3.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 5.8% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.4%). In line with average of industry peers (0.6%).Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥10.54 loss per share (down from JP¥24.36 profit in 3Q 2021). Revenue: JP¥2.94b (down 7.4% from 3Q 2021). Net loss: JP¥179.0m (down 142% from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 16Second quarter 2022 earnings released: EPS JP¥21.50 (vs JP¥2.02 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥3.39b (up 37% from 2Q 2021). Net income: JP¥373.0m (up JP¥338.0m from 2Q 2021). Profit margin: 11% (up from 1.4% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Sep 08Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC.Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC on September 7, 2021. As per terms of transaction, Lunapas LLC name will be changed to Lunapas Toxic Pathology Research Institute. March 31, 2021, Lunapas LLC reported Net assets of ¥15.5 million, Total assets of ¥19.736 million, Sales of ¥39.521 million, Operating income of ¥9.258 million and Net income of ¥7.445 million. transaction is expected to complete on November 1, 2021. Acquisition will have a minor impact on the business results for the fiscal year ending March 2022.Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥611, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 36x in the Biotechs industry in Japan. Total returns to shareholders of 32% over the past three years.お知らせ • Aug 26Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million.Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 550,000 shares, representing 3.17% of its issued share capital for ¥300 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till December 24, 2021. As of August 25, 2021, the company had 17,367,719 shares issued (excluding treasury stock) and 1,422 shares in treasury.Reported Earnings • Jun 29Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: JP¥11.0b (flat on FY 2020). Net income: JP¥546.0m (up JP¥986.0m from FY 2020). Profit margin: 4.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: JP¥11.0b (flat on FY 2020). Net income: JP¥546.0m (up JP¥986.0m from FY 2020). Profit margin: 4.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Reported Earnings • Feb 14Third quarter 2021 earnings released: EPS JP¥24.36 (vs JP¥1.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥3.18b (up 18% from 3Q 2020). Net income: JP¥423.0m (up JP¥405.0m from 3Q 2020). Profit margin: 13% (up from 0.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 68% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Jan 19New 90-day high: JP¥549The company is up 46% from its price of JP¥377 on 21 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 24New 90-day high: JP¥431The company is up 6.0% from its price of JP¥408 on 25 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period.お知らせ • Dec 04Trans Genic Inc. to Report Q3, 2021 Results on Feb 12, 2021Trans Genic Inc. announced that they will report Q3, 2021 results on Feb 12, 2021お知らせ • Sep 03Trans Genic Inc. to Report Q2, 2021 Results on Nov 12, 2020Trans Genic Inc. announced that they will report Q2, 2021 results on Nov 12, 2020株主還元2342JP BiotechsJP 市場7D-6.5%-6.9%1.4%1Y51.3%-28.8%43.3%株主還元を見る業界別リターン: 2342過去 1 年間で-28.8 % の収益を上げたJP Biotechs業界を上回りました。リターン対市場: 2342過去 1 年間で43.3 % の収益を上げたJP市場を上回りました。価格変動Is 2342's price volatile compared to industry and market?2342 volatility2342 Average Weekly Movement8.7%Biotechs Industry Average Movement8.6%Market Average Movement4.8%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.4%安定した株価: 2342の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 2342の 週次ボラティリティ は過去 1 年間で14%から9%に減少しましたが、依然としてJP株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1998241Kenji Fukunagatransgenic-group.co.jp株式会社トランスジェニック・グループは、日本における遺伝子組換え動物および抗体の開発、販売、ライセンスを行っています。創薬支援事業、投資・コンサルティング事業を展開。糖鎖合成・解析サービス、医薬品・食品・化粧品・化学物質等の非臨床試験、食品・医薬品等の各種安全性試験、臨床試験・薬物動態測定・臨床試験報告書作成等の生物学的同等性試験支援、病院支援サービスを提供。また、薬効・薬理試験、安全性試験、糖鎖解析・合成サービス、M&A・事業再生・事業承継サービスなどの助言・支援サービス、遺伝子改変マウス、抗体、プロテインハイパー、発現細胞などの受託製造サービス、マウス関連製品・マウスモデル、研究用試薬の販売も行っている。また、事業承継・事業再生、事業承継、投資事業コンサルティングなどの支援サービスも提供している。旧社名は株式会社トランスジェニックで、2024年10月に株式会社トランスジェニック・グループに商号変更した。株式会社トランスジェニック・グループは1998年に設立され、福岡市に本社を置く。もっと見るTransgenic Group Inc. 基礎のまとめTransgenic Group の収益と売上を時価総額と比較するとどうか。2342 基礎統計学時価総額JP¥3.83b収益（TTM）-JP¥77.00m売上高(TTM)JP¥13.17b0.3xP/Sレシオ-49.7xPER（株価収益率2342 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計2342 損益計算書（TTM）収益JP¥13.17b売上原価JP¥10.74b売上総利益JP¥2.43bその他の費用JP¥2.51b収益-JP¥77.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-4.62グロス・マージン18.47%純利益率-0.58%有利子負債／自己資本比率43.2%2342 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 21:48終値2026/06/05 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Transgenic Group Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 17Full year 2026 earnings released: JP¥4.62 loss per share (vs JP¥65.47 loss in FY 2025)Full year 2026 results: JP¥4.62 loss per share (improved from JP¥65.47 loss in FY 2025). Revenue: JP¥13.2b (up 1.3% from FY 2025). Net loss: JP¥77.0m (loss narrowed 93% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • May 13Transgenic Group Inc., Annual General Meeting, Jun 18, 2026Transgenic Group Inc., Annual General Meeting, Jun 18, 2026.
Reported Earnings • Feb 11Third quarter 2026 earnings released: JP¥0.06 loss per share (vs JP¥6.55 loss in 3Q 2025)Third quarter 2026 results: JP¥0.06 loss per share (improved from JP¥6.55 loss in 3Q 2025). Revenue: JP¥3.47b (flat on 3Q 2025). Net loss: JP¥1.00m (loss narrowed 99% from 3Q 2025). Profit margin: 0% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
分析記事 • Jan 15Is Transgenic Group (TSE:2342) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Dec 18Transgenic Group Inc. to Report Q3, 2026 Results on Feb 10, 2026Transgenic Group Inc. announced that they will report Q3, 2026 results on Feb 10, 2026
分析記事 • Nov 19Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) may be sending very bullish signals...
Reported Earnings • May 17Full year 2026 earnings released: JP¥4.62 loss per share (vs JP¥65.47 loss in FY 2025)Full year 2026 results: JP¥4.62 loss per share (improved from JP¥65.47 loss in FY 2025). Revenue: JP¥13.2b (up 1.3% from FY 2025). Net loss: JP¥77.0m (loss narrowed 93% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • May 13Transgenic Group Inc., Annual General Meeting, Jun 18, 2026Transgenic Group Inc., Annual General Meeting, Jun 18, 2026.
Reported Earnings • Feb 11Third quarter 2026 earnings released: JP¥0.06 loss per share (vs JP¥6.55 loss in 3Q 2025)Third quarter 2026 results: JP¥0.06 loss per share (improved from JP¥6.55 loss in 3Q 2025). Revenue: JP¥3.47b (flat on 3Q 2025). Net loss: JP¥1.00m (loss narrowed 99% from 3Q 2025). Profit margin: 0% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
分析記事 • Jan 15Is Transgenic Group (TSE:2342) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Dec 18Transgenic Group Inc. to Report Q3, 2026 Results on Feb 10, 2026Transgenic Group Inc. announced that they will report Q3, 2026 results on Feb 10, 2026
分析記事 • Nov 19Why Investors Shouldn't Be Surprised By Transgenic Group Inc.'s (TSE:2342) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) may be sending very bullish signals...
Reported Earnings • Nov 15Second quarter 2026 earnings released: EPS: JP¥0.18 (vs JP¥4.99 loss in 2Q 2025)Second quarter 2026 results: EPS: JP¥0.18 (up from JP¥4.99 loss in 2Q 2025). Revenue: JP¥3.03b (down 12% from 2Q 2025). Net income: JP¥3.00m (up JP¥86.0m from 2Q 2025). Profit margin: 0.1% (up from net loss in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 04Transgenic Group Inc. to Report Q2, 2026 Results on Nov 12, 2025Transgenic Group Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: JP¥1.56 (vs JP¥5.97 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥1.56 (up from JP¥5.97 loss in 1Q 2025). Revenue: JP¥3.20b (up 11% from 1Q 2025). Net income: JP¥26.0m (up JP¥125.0m from 1Q 2025). Profit margin: 0.8% (up from net loss in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 26Transgenic Group Inc. to Report Q1, 2026 Results on Aug 14, 2025Transgenic Group Inc. announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • Jun 19Full year 2025 earnings released: JP¥65.47 loss per share (vs JP¥0.24 profit in FY 2024)Full year 2025 results: JP¥65.47 loss per share (down from JP¥0.24 profit in FY 2024). Revenue: JP¥13.0b (flat on FY 2024). Net loss: JP¥1.09b (down JP¥1.09b from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
分析記事 • Jun 17Here's Why Transgenic Group (TSE:2342) Can Afford Some DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jun 17There's No Escaping Transgenic Group Inc.'s (TSE:2342) Muted Revenues Despite A 33% Share Price RiseTransgenic Group Inc. ( TSE:2342 ) shareholders would be excited to see that the share price has had a great month...
お知らせ • Jun 16Transgenic Group Inc., Annual General Meeting, Jun 30, 2025Transgenic Group Inc., Annual General Meeting, Jun 30, 2025.
分析記事 • Apr 15Little Excitement Around Transgenic Group Inc.'s (TSE:2342) RevenuesTransgenic Group Inc.'s ( TSE:2342 ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right...
New Risk • Apr 07New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥2.73b market cap, or US$18.7m).
お知らせ • Mar 12Transgenic Group Inc. to Report Fiscal Year 2025 Results on May 13, 2025Transgenic Group Inc. announced that they will report fiscal year 2025 results on May 13, 2025
Reported Earnings • Feb 17Third quarter 2025 earnings released: JP¥6.55 loss per share (vs JP¥5.10 loss in 3Q 2024)Third quarter 2025 results: JP¥6.55 loss per share (further deteriorated from JP¥5.10 loss in 3Q 2024). Revenue: JP¥3.50b (up 3.9% from 3Q 2024). Net loss: JP¥109.0m (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
New Risk • Dec 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥3.03b market cap, or US$19.2m).
お知らせ • Dec 04Transgenic Group Inc. to Report Q3, 2025 Results on Feb 14, 2025Transgenic Group Inc. announced that they will report Q3, 2025 results on Feb 14, 2025
Reported Earnings • Nov 18Second quarter 2025 earnings released: JP¥4.99 loss per share (vs JP¥1.78 loss in 2Q 2024)Second quarter 2025 results: JP¥4.99 loss per share (further deteriorated from JP¥1.78 loss in 2Q 2024). Revenue: JP¥3.43b (up 11% from 2Q 2024). Net loss: JP¥83.0m (loss widened 177% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 13Transgenic Group Inc.'s (TSE:2342) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Transgenic Group Inc. ( TSE:2342 ) is definitely a...
Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥5.97 loss per share (vs JP¥4.63 profit in 1Q 2024)First quarter 2025 results: JP¥5.97 loss per share (down from JP¥4.63 profit in 1Q 2024). Revenue: JP¥2.88b (down 12% from 1Q 2024). Net loss: JP¥99.0m (down 227% from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 26Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023)Full year 2024 results: EPS: JP¥0.24 (up from JP¥24.28 loss in FY 2023). Revenue: JP¥13.1b (up 14% from FY 2023). Net income: JP¥4.00m (up JP¥413.0m from FY 2023). Profit margin: 0% (up from net loss in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 20Trans Genic Inc. to Report Q1, 2025 Results on Aug 09, 2024Trans Genic Inc. announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • May 13Full year 2024 earnings released: EPS: JP¥0.24 (vs JP¥24.28 loss in FY 2023)Full year 2024 results: EPS: JP¥0.24 (up from JP¥24.28 loss in FY 2023). Revenue: JP¥13.1b (up 14% from FY 2023). Net income: JP¥4.00m (up JP¥413.0m from FY 2023). Profit margin: 0% (up from net loss in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance.
お知らせ • May 12Trans Genic Inc., Annual General Meeting, Jun 20, 2024Trans Genic Inc., Annual General Meeting, Jun 20, 2024.
分析記事 • Apr 27Improved Revenues Required Before Trans Genic Inc. (TSE:2342) Shares Find Their FeetTrans Genic Inc.'s ( TSE:2342 ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy right now...
Upcoming Dividend • Mar 21Upcoming dividend of JP¥3.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 24 June 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.2%). In line with average of industry peers (1.2%).
お知らせ • Mar 06Trans Genic Inc. to Report Fiscal Year 2024 Results on May 10, 2024Trans Genic Inc. announced that they will report fiscal year 2024 results on May 10, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥5.10 loss per share (vs JP¥7.59 profit in 3Q 2023)Third quarter 2024 results: JP¥5.10 loss per share (down from JP¥7.59 profit in 3Q 2023). Revenue: JP¥3.37b (up 15% from 3Q 2023). Net loss: JP¥86.0m (down 167% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.
New Risk • Jan 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥4.45b market cap, or US$30.2m).
お知らせ • Nov 29Trans Genic Inc. to Report Q3, 2024 Results on Feb 09, 2024Trans Genic Inc. announced that they will report Q3, 2024 results on Feb 09, 2024
お知らせ • Nov 24Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 300,000 shares, representing 1.78% for ¥100 million.Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 300,000 shares, representing 1.78% of its issued share capital, for ¥100 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till March 22, 2024. As of November 22, 2023, the company had 16,893,719 shares issued (excluding treasury stock) and 105,422 shares in treasury.
Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥4.69 profit in 2Q 2023)Second quarter 2024 results: JP¥1.78 loss per share (down from JP¥4.69 profit in 2Q 2023). Revenue: JP¥3.10b (flat on 2Q 2023). Net loss: JP¥30.0m (down 138% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 15Trans Genic Inc. to Report Q2, 2024 Results on Nov 10, 2023Trans Genic Inc. announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 14First quarter 2024 earnings released: EPS: JP¥4.63 (vs JP¥1.49 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥4.63 (up from JP¥1.49 loss in 1Q 2023). Revenue: JP¥3.28b (up 33% from 1Q 2023). Net income: JP¥78.0m (up JP¥103.0m from 1Q 2023). Profit margin: 2.4% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 28Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022)Full year 2023 results: JP¥24.28 loss per share (down from JP¥110 profit in FY 2022). Revenue: JP¥11.4b (down 9.1% from FY 2022). Net loss: JP¥409.0m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jun 21Trans Genic Inc. to Report Q1, 2024 Results on Aug 10, 2023Trans Genic Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
Reported Earnings • May 18Full year 2023 earnings released: JP¥24.28 loss per share (vs JP¥110 profit in FY 2022)Full year 2023 results: JP¥24.28 loss per share (down from JP¥110 profit in FY 2022). Revenue: JP¥11.4b (down 9.1% from FY 2022). Net loss: JP¥409.0m (down 122% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥5.00 per share at 0.9% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 26 June 2023. Payout ratio is a comfortable 4.0% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (1.0%).
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: JP¥7.59 (vs JP¥10.54 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥7.59 (up from JP¥10.54 loss in 3Q 2022). Revenue: JP¥2.92b (flat on 3Q 2022). Net income: JP¥128.0m (up JP¥307.0m from 3Q 2022). Profit margin: 4.4% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Dec 21Trans Genic Inc. to Report Q3, 2023 Results on Feb 10, 2023Trans Genic Inc. announced that they will report Q3, 2023 results on Feb 10, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022)Second quarter 2023 results: EPS: JP¥4.69 (down from JP¥21.50 in 2Q 2022). Revenue: JP¥3.07b (down 9.4% from 2Q 2022). Net income: JP¥79.0m (down 79% from 2Q 2022). Profit margin: 2.6% (down from 11% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Hotaka Saito was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: JP¥4.69 (vs JP¥21.50 in 2Q 2022)Second quarter 2023 results: EPS: JP¥4.69 (down from JP¥21.50 in 2Q 2022). Revenue: JP¥3.07b (down 9.4% from 2Q 2022). Net income: JP¥79.0m (down 79% from 2Q 2022). Profit margin: 2.6% (down from 11% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Sep 02Trans Genic Inc. to Report Q2, 2023 Results on Nov 11, 2022Trans Genic Inc. announced that they will report Q2, 2023 results on Nov 11, 2022
Reported Earnings • Aug 14First quarter 2023 earnings released: JP¥1.49 loss per share (vs JP¥35.01 profit in 1Q 2022)First quarter 2023 results: JP¥1.49 loss per share (down from JP¥35.01 profit in 1Q 2022). Revenue: JP¥2.47b (down 25% from 1Q 2022). Net loss: JP¥25.0m (down 104% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Jun 23Trans Genic Inc. to Report Q1, 2023 Results on Aug 12, 2022Trans Genic Inc. announced that they will report Q1, 2023 results on Aug 12, 2022
Reported Earnings • May 16Full year 2022 earnings released: EPS: JP¥110 (vs JP¥31.44 in FY 2021)Full year 2022 results: EPS: JP¥110 (up from JP¥31.44 in FY 2021). Revenue: JP¥12.6b (up 14% from FY 2021). Net income: JP¥1.88b (up 244% from FY 2021). Profit margin: 15% (up from 4.9% in FY 2021). Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • May 15Trans Genic Inc., Annual General Meeting, Jun 23, 2022Trans Genic Inc., Annual General Meeting, Jun 23, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Outside Director Hotaka Saito was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 07Trans Genic Inc. to Report Fiscal Year 2022 Results on May 13, 2022Trans Genic Inc. announced that they will report fiscal year 2022 results on May 13, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥3.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 5.8% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.4%). In line with average of industry peers (0.6%).
Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥10.54 loss per share (down from JP¥24.36 profit in 3Q 2021). Revenue: JP¥2.94b (down 7.4% from 3Q 2021). Net loss: JP¥179.0m (down 142% from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 16Second quarter 2022 earnings released: EPS JP¥21.50 (vs JP¥2.02 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥3.39b (up 37% from 2Q 2021). Net income: JP¥373.0m (up JP¥338.0m from 2Q 2021). Profit margin: 11% (up from 1.4% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Sep 08Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC.Trans Genic Inc. (TSE:2342) entered into share transfer agreement to acquire Lunapas LLC on September 7, 2021. As per terms of transaction, Lunapas LLC name will be changed to Lunapas Toxic Pathology Research Institute. March 31, 2021, Lunapas LLC reported Net assets of ¥15.5 million, Total assets of ¥19.736 million, Sales of ¥39.521 million, Operating income of ¥9.258 million and Net income of ¥7.445 million. transaction is expected to complete on November 1, 2021. Acquisition will have a minor impact on the business results for the fiscal year ending March 2022.
Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥611, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 36x in the Biotechs industry in Japan. Total returns to shareholders of 32% over the past three years.
お知らせ • Aug 26Trans Genic Inc. (TSE:2342) announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million.Trans Genic Inc. (TSE:2342) announces a share repurchase program. Under the program, the company will repurchase up to 550,000 shares, representing 3.17% of its issued share capital for ¥300 million. The purpose of the program is agile capital policy implementation and shareholder return measures in response to changes in the business environment. The program is valid till December 24, 2021. As of August 25, 2021, the company had 17,367,719 shares issued (excluding treasury stock) and 1,422 shares in treasury.
Reported Earnings • Jun 29Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: JP¥11.0b (flat on FY 2020). Net income: JP¥546.0m (up JP¥986.0m from FY 2020). Profit margin: 4.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥31.44 (vs JP¥25.33 loss in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: JP¥11.0b (flat on FY 2020). Net income: JP¥546.0m (up JP¥986.0m from FY 2020). Profit margin: 4.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 14Third quarter 2021 earnings released: EPS JP¥24.36 (vs JP¥1.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥3.18b (up 18% from 3Q 2020). Net income: JP¥423.0m (up JP¥405.0m from 3Q 2020). Profit margin: 13% (up from 0.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 68% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Jan 19New 90-day high: JP¥549The company is up 46% from its price of JP¥377 on 21 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 24New 90-day high: JP¥431The company is up 6.0% from its price of JP¥408 on 25 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period.
お知らせ • Dec 04Trans Genic Inc. to Report Q3, 2021 Results on Feb 12, 2021Trans Genic Inc. announced that they will report Q3, 2021 results on Feb 12, 2021
お知らせ • Sep 03Trans Genic Inc. to Report Q2, 2021 Results on Nov 12, 2020Trans Genic Inc. announced that they will report Q2, 2021 results on Nov 12, 2020
